|
1
|
Zahid M and Robbins PD: Cell-type specific
penetrating peptides: Therapeutic promises and challenges.
Molecules. 20:13055–13070. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gautam A, Singh H, Tyagi A, Chaudhary K,
Kumar R, Kapoor P and Raghava GP: CPPsite: A curated database of
cell penetrating peptides. Database (Oxford). 2012:bas0152012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Madani F, Lindberg S, Langel U, Futaki S
and Gräslund A: Mechanisms of cellular uptake of cell-penetrating
peptides. J Biophys. 2011:4147292011.PubMed/NCBI
|
|
4
|
Jiao CY, Delaroche D, Burlina F, Alves ID,
Chassaing G and Sagan S: Translocation and endocytosis for
cell-penetrating peptide internalization. J Biol Chem.
284:33957–33965. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Elliott G and O'Hare P: Intercellular
trafficking and protein delivery by a herpesvirus structural
protein. Cell. 88:223–233. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tanaka M, Kato A, Satoh Y, Ide T, Sagou K,
Kimura K, Hasegawa H and Kawaguchi Y: Herpes simplex virus 1 VP22
regulates translocation of multiple viral and cellular proteins and
promotes neurovirulence. J Virol. 86:5264–5277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zavaglia D, Favrot MC, Eymin B, Tenaud C
and Coll JL: Intercellular trafficking and enhanced in vivo
antitumour activity of a non-virally delivered P27-VP22 fusion
protein. Gene Ther. 10:314–325. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jin G, Zhou Y, Chai Q, Zhu G, Xu F and Liu
F: VP22 and cytosine deaminase fusion gene modified
tissue-engineered neural stem cells for glioma therapy. J Cancer
Res Clin Oncol. 139:475–483. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nishikawa M, Otsuki T, Ota A, Guan X,
Takemoto S, Takahashi Y and Takakura Y: Induction of tumor-specific
immune response by gene transfer of Hsp70-cell-penetrating peptide
fusion protein to tumors in mice. Mol Ther. 18:421–428. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bian J, Popovic ZB, Benejam C, Kiedrowski
M, Rodriguez LL and Penn MS: Effect of cell-based intercellular
delivery of transcription factor GATA4 on ischemic cardiomyopathy.
Circ Res. 100:1626–1633. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu X, Liu L, Wu L, Wang L, Dong C, Li W
and Li Q: Herpes simplex virus type 1 tegument protein VP22 is
capable of modulating the transcription of viral TK and gC genes
via interaction with viral ICP0. Biochimie. 92:1024–1030. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Z, Feng S, Huang Y, Qiao M, Zhang B
and Xu H: Prokaryotic expression, purification and polyclonal
antibody production of a hydrophobin from Grifola frondosa. Acta
Biochim Biophys Sin (Shanghai). 42:388–395. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bolhassani A: Potential efficacy of
cell-penetrating peptides for nucleic acid and drug delivery in
cancer. Biochim Biophys Acta. 1816:232–246. 2011.PubMed/NCBI
|
|
14
|
Sawant R and Torchilin V: Intracellular
transduction using cell-penetrating peptides. Mol Biosyst.
6:628–640. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aints A, Güven H, Gahrton G, Smith CI and
Dilber MS: Mapping of herpes simplex virus-1 VP22 functional
domains for inter-and subcellular protein targeting. Gene Ther.
8:1051–1056. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Perkins SD, Flick-Smith HC, Garmory HS,
Essex-Lopresti AE, Stevenson FK and Phillpotts RJ: Evaluation of
the VP22 protein for enhancement of a DNA vaccine against anthrax.
Genet Vaccines. 3:32005. View Article : Google Scholar
|
|
17
|
Mouzakitis G, McLauchlan J, Barreca C,
Kueltzo L and O'Hare P: Characterization of VP22 in Herpes simplex
virus-infected cells. J Virol. 79:12185–12198. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yedowitz JC, Kotsakis A, Schlegel EF and
Blaho JA: Nuclear localizations of the herpes simplex virus type 1
tegument proteins VP13/14, vhs and VP16 precedeVP22-dependent
microtubule reorganization and VP22 nuclear import. J Virol.
79:4730–4743. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi NQ, Qi XR, Xiang B and Zhang Y: A
survey on ‘Trojan Horse’ peptides: Opportunities, issues and
controlled entry to ‘Troy’. J Control Release. 194:53–70. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu X, Xu Z, Lei J, Li T and Wang Y: VP22
mediates intercellular trafficking and enhances the in vitro
antitumor activity of PTEN. Mol Med Rep. 12:1286–1290.
2015.PubMed/NCBI
|
